Table 4.
Facility characteristics | ANZ | Canada | Japan | Thailand | UK | USA |
---|---|---|---|---|---|---|
Number of facilities | 18 | 20 | 28 | 22 | 17 | 65 |
Antibiotics at home prior to seeking medical attention, % | ||||||
Yes, all patients | 6 | 10 | 0 | 0 | 0 | 40 |
Yes, some patients | 0 | 20 | 15 | 5 | 6 | 11 |
No patients | 94 | 70 | 85 | 96 | 94 | 49 |
After-hours nurse provides care at PD facility, % | 7 | 25 | 33 | 55 | 12 | 55 |
Number of antibiotics against Pseudomonas aeruginosa, % | ||||||
1 only | 11 | 5 | 56 | 27 | 29 | 15 |
2 | 89 | 95 | 44 | 68 | 65 | 83 |
>2 | 0 | 0 | 0 | 5 | 6 | 2 |
Initial antibiotic administration for treatment of an exit-site infection, % | ||||||
Oral | 83 | 75 | 68 | 82 | 71 | 73 |
Intraperitoneal | 17 | 0 | 7 | 0 | 18 | 19 |
Topical | 0 | 25 | 25 | 18 | 12 | 8 |
Initial antibiotic administration for PD catheter tunnel infection, % | ||||||
Oral | 28 | 50 | 86 | 57 | 53 | 43 |
Intraperitoneal | 61 | 45 | 4 | 10 | 18 | 56 |
Other | 11 | 5 | 11 | 33 | 29 | 2 |
Empiric antibiotic treatment for peritonitisa, % | ||||||
First-generation cephalosporin | 72 | 70 | 63 | 91 | 0 | 40 |
Second- or third-generation cephalosporin | 33 | 50 | 63 | 91 | 12 | 60 |
Vancomycin | 33 | 45 | 15 | 10 | 88 | 83 |
Aminoglycoside | 72 | 45 | 26 | 10 | 77 | 32 |
Other | 11 | 35 | 37 | 10 | 41 | 17 |
Medical directors could choose more than one answer so column percentages may not add up to 100%.